1. Home
  2. CXDO vs DTIL Comparison

CXDO vs DTIL Comparison

Compare CXDO & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CXDO

Crexendo Inc.

HOLD

Current Price

$5.93

Market Cap

189.9M

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$6.69

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXDO
DTIL
Founded
1995
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.9M
197.9M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
CXDO
DTIL
Price
$5.93
$6.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$9.20
$45.00
AVG Volume (30 Days)
257.0K
221.1K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
166.67
N/A
EPS
0.05
N/A
Revenue
$68,167,000.00
$1,070,000,000.00
Revenue This Year
$45.26
N/A
Revenue Next Year
$13.31
N/A
P/E Ratio
$115.80
N/A
Revenue Growth
12.05
N/A
52 Week Low
$5.54
$3.53
52 Week High
$11.23
$9.62

Technical Indicators

Market Signals
Indicator
CXDO
DTIL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CXDO
DTIL

About CXDO Crexendo Inc.

Crexendo Inc is a software technology company that provides cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services. The company operates through two segments: Cloud Telecommunications Services and Software Solutions. Its cloud telecommunications segment generates revenue from the provision of broadband Internet services, managed IT services, software license sales, and infrastructure as a service. The software solutions segment derives revenues from three primary sources: software licenses, software maintenance support and professional services. The majority of the company's revenue is derived from the Cloud Telecommunications Services segment.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: